SCHEMBL256756

SCHEMBL256756

Bc1ccc(C(=O)O)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
CYP1A2 P05177 1/20 0.42
RARB P10826 4/20 0.41
RARA P10276 3/20 0.41
RARG P13631 2/20 0.41
ALB P02768 1/20 0.41
KEAP1 Q14145 2/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39
ALDH1A1 P00352 3/20 0.39
TSHR P16473 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27665336 0.98 CES2 (0.42) CES2CES1CYP1A2RARBRARA
SCHEMBL14553949 0.83 CES2 (0.43) CES2CES1CYP1A2ALBKEAP1
SCHEMBL17249495 0.81 ALDH1A1 (0.52) CES2CES1ALDH1A1DGAT1SMN1; SMN2
SCHEMBL13652578 0.79 ALDH1A1 (0.48) CYP1A2ALDH1A1TSHRCA12CA1
SCHEMBL25667839 0.78 CES2 (0.39) CES2CES1DGAT1
SCHEMBL16534058 0.77 RARB (0.60) CES2CES1CYP1A2RARBRARA
SCHEMBL30641680 0.77 RARB (0.60) CES2CES1CYP1A2RARBRARA
SCHEMBL366061 0.77 CES2 (0.71) CES2CES1CYP1A2ALBKEAP1
SCHEMBL8109850 0.76 CA12 (0.46) CES2CES1ALDH1A1TSHRCA12
SCHEMBL14535151 0.76 CES2 (0.38) CES2CES1ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3453707-B1 BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2022-02-16 EP disclosed
EP-2982674-B1 PYRIDINYLPYRAZOLOQUINOLINE COMPOUND EISAI R&D MAN CO LTD (JP) 2017-10-25 EP disclosed
CN-103200820-B As the substd quinolines compound of GSNO reductase inhibitor Nivalis Therapeutics (US) 2016-04-06 CN disclosed
EP-2982674-A1 PYRIDINYLPYRAZOLOQUINOLINE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2016-02-10 EP disclosed
EP-1841504-B1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-11-19 EP disclosed
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed
WO-2011148922-A1 NOVEL QUINAZOLINE COMPOUND 田辺三菱製薬株式会社 (JP) 2011-12-01 WO disclosed
WO-2009100171-A1 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-13 WO disclosed
WO-2009018656-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-12 WO disclosed